Axel Vater
Berlin, Germany
Dr. Axel Vater, Chief Scientific Officer of Aptarion Biotech AG received his training as an Engineer in Biotechnology at the Technische Universität Berlin, Germany, including a research semester at Harvard Medical School. He received his PhD from TU Berlin for experimental work on L-configured aptamers performed at Noxxon Pharma.
He subsequently joined the in vivo imaging division of Schering/later Bayer.
After three years in “Big Pharma” Axel returned to Noxxon overseeing the generation and (pre‑)clinical development of new L-aptamers in various disease areas with special interest in targeting the tumor microenvironment and the complement system.
Axel now continues his work on the development of L-aptamers for life-threatening diseases as CSO of Aptarion Biotech, which he co-founded in 2016. Aptarion’s lead asset, the C5a-neutralizing L-aptamer AON-D21, is currently being tested in a Phase 2 trial in 150 patients with severe community-acquired pneumonia across western Europe.
